Peripheral sub-inflammation is associated with antidepressant consumption in schizophrenia. Results from the multi-center FACE-SZ data set

G. Fond, O. Godin, L. Brunel, B. Aouizerate, F. Berna, E. Bulzacka, D. Capdevielle, I. Chereau, J.M. Dorey, C. Dubertret, J. Dubreucq, C. Faget, F. Gabayet, Y. Le Strat, J.A. Micoulaud-Franchi, D. Misdrahi, R. Rey, R. Richieri, C. Passerieux, A. Schandrin, F. Schürhoff, A.M. Tronche, M. Urbach, P. Vidalhet, P.M. Llorca, M. Leboyer
Journal of Affective Disorders. 2016-02-01; 191: 209-215
DOI: 10.1016/j.jad.2015.11.017

PubMed
Lire sur PubMed



1. J Affect Disord. 2016 Feb;191:209-15. doi: 10.1016/j.jad.2015.11.017. Epub 2015
Nov 26.

Peripheral sub-inflammation is associated with antidepressant consumption in
schizophrenia. Results from the multi-center FACE-SZ data set.

Fond G(1), Godin O(2), Brunel L(1), Aouizerate B(3), Berna F(4), Bulzacka E(1),
Capdevielle D(5), Chereau I(6), Dorey JM(7), Dubertret C(8), Dubreucq J(9), Faget
C(10), Gabayet F(9), Le Strat Y(8), Micoulaud-Franchi JA(11), Misdrahi D(12), Rey
R(7), Richieri R(10), Passerieux C(13), Schandrin A(5), Schürhoff F(1), Tronche
AM(6), Urbach M(13), Vidalhet P(14), Llorca PM(6), Leboyer M(1); FACE-SZ
(FondaMental Academic Centers of Expertise for Schizophrenia) group.

Collaborators: Aouizerate B, Berna F, Blanc O, Brunel L, Bulzacka E, Capdevielle
D, Chereau-Boudet I, Chesnoy-Servanin G, Danion JM, D’ Amato T, Deloge A, Delorme
C, Denizot H, DePradier M, Dorey JM, Dubertret C, Dubreucq J, Faget C, Fluttaz C,
Fond G, Fonteneau S, Gabayet F, Giraud-Baro E, Hardy-Bayle MC, Lacelle D, Lançon
C, Laouamri H, Leboyer M, LeGloahec T, LeStrat Y, Llorca PM, Metairie E, Misdrahi
D, Offerlin-Meyer I, Passerieux C, Peri P, Pires S, Portalier C, Rey R, Roman C,
Sebilleau M, Schandrin A, Schürhoff F, Tessier A, Tronche AM, Urbach M, Vaillant
F, Vehier A, Vidailhet P, Vilà E, Yazbek H, Zinetti-Bertschy A.

Author information:
(1)Fondation FondaMental, Créteil, France; INSERM U955, Translational Psychiatry
team, Créteil, France, Paris Est University, DHU Pe-PSY, Pôle de Psychiatrie des
Hôpitaux Universitaires H Mondor, Créteil, France.
(2)Fondation FondaMental, Créteil, France; Sorbonne Universités, UPMC Univ Paris
06, UMR_S 1136, Institut Pierre Louis d’Epidémiologie et de Santé Publique,
INSERM, F-75013, Paris, France.
(3)Fondation FondaMental, Créteil, France; Centre Hospitalier Charles Perrens,
Université de Bordeaux, F-33076 Bordeaux, France; Inserm, Neurocentre Magendie,
Physiopathologie de la Plasticité Neuronale, U862, F-33000 Bordeaux, France.
(4)Fondation FondaMental, Créteil, France; Hôpitaux Universitaires de Strasbourg,
Université de Strasbourg, INSERM U1114, Fédération de Médecine Translationnelle
de Strasbourg, Strasbourg, France.
(5)Fondation FondaMental, Créteil, France; Service Universitaire de Psychiatrie
Adulte, Hôpital la Colombière, CHRU Montpellier, Université Montpellier 1, Inserm
1061, Montpellier, France.
(6)Fondation FondaMental, Créteil, France; CMP B, CHU, EA 7280 Faculté de
Médecine, Université d’Auvergne, BP 69 63003 Clermont-Ferrand Cedex 1, France.
(7)Fondation FondaMental, Créteil, France; Université Claude Bernard Lyon
1/Centre Hospitalier Le Vinatier Pole Est BP 300 39 – 95 bd Pinel – 69678 BRON
Cedex, France.
(8)Fondation FondaMental, Créteil, France; AP-HP, Department of Psychiatry, Louis
Mourier Hospital, Colombes, Inserm U894, Université Paris Diderot, Sorbonne Paris
Cité, Faculté de médecine, France.
(9)Fondation FondaMental, Créteil, France; Centre Référent de Réhabilitation
Psychosociale, CH Alpes Isère, Grenoble, France.
(10)Fondation FondaMental, Créteil, France; Assistance Publique des Hôpitaux de
Marseille (AP-HM), pôle universitaire de psychiatrie, Marseille, France.
(11)Bordeaux Sleep Clinique, Pellegrin University Hospital, Bordeaux University,
USR CNRS 3413 SANPSY, Research Unit, 33000 Bordeaux, France.
(12)Fondation FondaMental, Créteil, France; Centre Hospitalier Charles Perrens,
Université de Bordeaux, F-33076 Bordeaux, France; CNRS UMR 5287-INCIA, France.
(13)Fondation FondaMental, Créteil, France; Service de psychiatrie d’adulte,
Centre Hospitalier de Versailles, UFR des Sciences de la Santé Simone Veil,
Université Versailles Saint-Quentin en Yvelines, Versailles, France.
(14)Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, INSERM
U1114, Fédération de Médecine Translationnelle de Strasbourg, Strasbourg, France.

OBJECTIVES: The relation between C-Reactive Protein (CRP), depression and
antidepressant consumption has been well explored in major depressive disorders
but not in schizophrenia, which has a high rate of depression comorbidity. The
objectives of this study were: (i) to determine the prevalence of abnormal CRP
levels, depression and antidepressant consumption in a multicenter
community-dwelling sample of subjects with schizophrenia (ii) to determine the
association between abnormal CRP levels, depression and antidepressant
consumption in schizophrenia.
METHOD: 219 stable patients with schizophrenia (mean age=31.6 years, 75.3% male
gender) were systematically included in the multicentre network of FondaMental
Expert Center for schizophrenia (FACE-SZ) and assessed with a dedicated
electronic medical record including the Structured Clinical Interview for DSM-IV
Axis I Disorders and Calgary Depression Scale for depression. High sensitivity
CRP (hs-CRP) was measured with an assay using nephelometry (Dade Behring).
Abnormal CRP level was defined by levels >3mg/L. Current medication was recorded.
RESULTS: Overall, 63 subjects (28.8%) were found to have abnormal CRP levels, 43
(20.1%) received a diagnosis of comorbid current depression, and 51 (31.9%) had
ongoing antidepressant treatment. In univariate analysis, abnormal CRP levels
were found to be significantly associated with body mass index (BMI) (p

Auteurs Bordeaux Neurocampus